Resource impact statement

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population). This is because the guidance covers a small population of around 300 people.

The guidance requires FLT3 gene mutation analysis earlier after the initial diagnostic blood and bone marrow sampling than is current practice (within 7 days instead of 2 to 4 weeks), which may increase costs. But even if the cost doubled to £300 per test, the total would still be below £5 million per year in England.

The list price of midostaurin has a discount that is commercial in confidence. For enquiries about the patient access scheme contact commercial.team@novartis.com.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.


This page was last updated: 13 June 2018